Granulocyte colony-stimulating factor-mediated pain relieving therapy for spinal cord lesion-related neuropathic pain syndrome: a prospective, single-blinded, placebo controlled, dose-response trial

Phase 2

• Conditions: spinal cord lesion-related neuropathic pain syndrome

• Registration Number: JPRN-UMIN000012486
• Lead Sponsor: Chiba University Hospiotal

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-22
• Study Completion: 2016-01-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1. Allergy for drugs to be tested. 2. History of hematologic malignancy. 3. Recent history (~5 years) of malignant disease. 4. Acute myocardial infarction or angina pectoris under treatment. 5. History or tendency of thorombosis or thoromboembolism. 6. Splenomegary. 7. Consciousness diorder. 8. Pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Pain reduction 1 month after drug administration (evaluated by numerical rating scale)

Secondary Outcome Measures

Name	Time	Method
1. ratio of the patients showing 30% or 50% pain reduction 1 month after drug administration 2. Alteration of the score of Neuropathic pain symptoms inventory 3. Quantitative evaluation for neuropathic pain 4. QOL measure (EQ-5D)